What is an earnout and how does it work in a dental practice sale?

An earnout is the contingent portion of a practice sale — commonly 10 to 30 percent of the deal value — paid over the following two to three years only if the practice hits agreed performance targets. It typically enters the deal when the buyer's Quality of Earnings review cuts the price: rather than renegotiate the headline, the buyer substitutes contingent payments for the difference. The structural catch is that after closing, the buyer controls the operations that produce the performance, models the targets, and calculates the results from their own books.

What is the difference between cash and equity structure in a DSO deal?

A DSO deal's headline divides into components with fundamentally different risk. Cash at close — typically 40 to 60 percent of the stated value — is a fact. An escrow holdback (15 to 20 percent, held 24 to 36 months) is a probability the buyer can charge claims against. Rollover equity (20 to 40 percent, as stock in the buyer's platform) is a thesis about someone else's company. And an earnout (10 to 30 percent, contingent on future targets) is a wager refereed by your counterparty. Comparing offers on the headline number without pricing each component's risk is how sellers choose the worse deal with the bigger number.

Why do buyers use earnouts instead of paying cash?

Officially, to bridge valuation gaps and align incentives — and sometimes that is true. Mechanically, an earnout converts price risk into the seller's problem: when diligence findings cut the valuation, the buyer preserves the headline by making part of it contingent, keeps their cash outlay lower, and retains control of the very operations that determine whether the contingent portion is ever paid. It also transfers execution risk — if integration underperforms, the buyer's cost of the acquisition falls automatically.

What are the risks of an earnout for the seller?

Three structural ones, before any bad faith: the targets are built on the buyer's model of your future; the post-close operations that produce the results — scheduling, fees, staffing, compensation, compliance protocols — are controlled by the buyer; and performance is measured on the buyer's books under the buyer's accounting policies. A common failure sequence: the buyer enforces compliance on day one, previously aggressive coding normalizes, revenue drops through no new decision of the seller's, and targets built on the old revenue quietly become unreachable. Every point you score costs the grader exactly one point.

How are earnout payments taxed?

Often worse than the sale itself. The IRS frequently scrutinizes contingent payments, and amounts tied to the seller's continued employment or personal performance can be reclassified from capital gains to ordinary income — a materially higher rate on money that was already uncertain. Treatment depends entirely on structure: how the earnout is documented, what it is contingent on, and how payments are characterized. This is general information, not tax advice — model the earnout's after-tax value with your CPA before signing, not after.

How do I negotiate earnout protections in a practice sale?

Five clauses carry most of the protection. One: base targets on metrics you influence — collections, not platform-level EBITDA that absorbs someone else's overhead. Two: freeze measurement definitions in the agreement — accounting policies, inclusions, exclusions. Three: operating covenants committing the buyer not to change the conditions the targets were built on — staffing, scheduling, fee schedules. Four: audit rights with a dispute mechanism short of litigation, and the intent to actually use them. Five: acceleration triggers — if the buyer sells the platform or changes your role, the earnout pays out. And the strongest protection precedes the deal: EBITDA that survives diligence intact never gets converted into an earnout at all.

Financial Analytics

The Graded Exam: Why Your Earnout Is Scored by the Person Who Owes the Money

James DeLuca August 10, 2026 8 min read

Imagine taking the most important exam of your life. Now imagine the person grading it owes you a million dollars if you pass.

That is an earnout. And nobody at the closing dinner describes it that way.

Here is how it appears instead: the buyer’s offer arrives at a number you like, but not all of it is cash. Ten to thirty percent of the deal is “contingent consideration” — paid over the next two or three years if the practice hits agreed performance targets. The banker calls it aligned incentives. The buyer calls it standard structure. It sounds like the price, delayed.

Read the mechanics instead.

Who writes the test

The earnout targets are negotiated — but they are built on the buyer’s model of the practice’s future. The same diligence team that just spent ninety days recalculating your EBITDA downward now projects the revenue you’ll need to hit for the next payment. You are betting on a forecast produced by the counterparty who profits if you miss it.

Who controls the classroom

The day after closing, you don’t run the practice anymore. They do. Your schedule, your fee negotiations, your staffing, your compensation model, your team’s targets — set by the platform, based on what the platform needs: debt service, investor returns, EBITDA projections for their next recapitalization.

Then the compliance layer arrives. The buyer’s protocols get enforced on day one — and when aggressive coding gets neutralized and production normalizes, revenue drops through no new decision of yours. The practice performs exactly as the buyer’s own compliance math predicted. And the earnout target, built on the old revenue, quietly slides out of reach.

Follow the sequence: they cut the price in diligence, substituted an earnout for the difference, changed the operating conditions, and then measured you against a number produced under conditions that no longer exist.

Who grades the answer

At measurement time, the practice’s performance is calculated from the buyer’s books, under the buyer’s accounting policies, by the buyer’s team. Most sellers have audit rights buried in the agreement. Almost none exercise them. The exam is scored by the party writing the check — and every point you score costs them exactly one point.

None of this requires bad faith. That’s what makes it dangerous. Every participant can behave professionally, and the structure still tilts the table — because the structure hands one side the pen, the classroom, and the grade.

The tax insult on top

One more mechanic sellers discover late: the IRS frequently treats contingent earnout payments less favorably than the sale itself — payments tied to your continued employment or performance can be reclassified from capital gains to ordinary income. Worse odds, and a worse rate on whatever you win. (Structure decides everything at the closing table — this is exactly the conversation to have with your CPA before signing, not after.)

The taxonomy, completed

A few weeks ago I wrote that a deal’s headline number is really three different assets: cash at close is a fact, escrow is a probability, rollover equity is a thesis about someone else’s company.

The earnout completes the set: a wager, refereed by your counterparty.

Component	Typical share	What it actually is
Cash at close	40–60%	A fact
Escrow holdback, 24–36 months	15–20%	A probability — chargeable against claims
Rollover equity	20–40%	A thesis — stock in the buyer’s platform
Earnout, 2–3 years	10–30%	A wager — refereed by your counterparty

Source: Precision Dental Analytics; component ranges per prevailing DSO deal terms. Ranges overlap because deals mix components — no single deal carries all four at maximum.

On a $4,000,000 headline structured at 60% cash, 15% escrow, and 25% earnout: $2,400,000 is a fact. $600,000 is a probability. And $1,000,000 is a bet that a practice you no longer control, operating under conditions you didn’t set, will hit targets modeled by the person who pays out if you win.

The defense

Earnouts are not always avoidable — sometimes they bridge a real valuation gap, and sometimes they’re the best available structure. But they are negotiable in every dimension that matters:

Targets based on metrics you influence — collections, not platform-level EBITDA someone else’s overhead flows into.
Measurement definitions frozen in the agreement — accounting policies, what counts, what doesn’t.
Operating covenants: the buyer commits to not changing the conditions the targets were built on — staffing levels, your schedule, fee schedules.
Audit rights you will actually use, with a dispute mechanism that doesn’t require litigation.
Acceleration triggers: if they sell the platform or change your role, the earnout pays.

And the meta-defense is the one this work always lands on: the sellers who take the least earnout risk are the ones whose numbers survived diligence intact — because the earnout substitution happens when the QoE cuts the price. Defensible EBITDA isn’t just a bigger number. It’s a bigger share of the deal in cash, where no one grades you.

An exam scored by the person who owes the money isn’t an exam. It’s a negotiation you already left the room for.

Want the full deal-mechanics education, live? PDA is producing The Practice Owner’s Playbook — a free five-session series where an M&A director covers exactly this territory: buyer types, deal structures, and what “selling twice” really means. Save a seat →

Educational, not legal, tax, or financial advice — earnout structures and tax treatment vary by deal; negotiate yours with your attorney and CPA at the table. To see what a buyer’s diligence will find before they do, run the EBITDA Leakage Diagnostic.

About the author — James DeLuca is the founder of Precision Dental Analytics and a leading expert in Clinical Data Forensics and M&A Defense. Acting as the elite “Red Team” for multi-location founders and sell-side brokers, he mathematically hardens clinical architecture before founders face institutional due diligence. He is the author of Phantom EBITDA, Spartan Leadership, The Dental Data Playbook, and Hidden Levers. Meet the team →

Frequently Asked

Questions

What is an earnout and how does it work in a dental practice sale?: An earnout is the contingent portion of a practice sale — commonly 10 to 30 percent of the deal value — paid over the following two to three years only if the practice hits agreed performance targets. It typically enters the deal when the buyer's Quality of Earnings review cuts the price: rather than renegotiate the headline, the buyer substitutes contingent payments for the difference. The structural catch is that after closing, the buyer controls the operations that produce the performance, models the targets, and calculates the results from their own books.
What is the difference between cash and equity structure in a DSO deal?: A DSO deal's headline divides into components with fundamentally different risk. Cash at close — typically 40 to 60 percent of the stated value — is a fact. An escrow holdback (15 to 20 percent, held 24 to 36 months) is a probability the buyer can charge claims against. Rollover equity (20 to 40 percent, as stock in the buyer's platform) is a thesis about someone else's company. And an earnout (10 to 30 percent, contingent on future targets) is a wager refereed by your counterparty. Comparing offers on the headline number without pricing each component's risk is how sellers choose the worse deal with the bigger number.
Why do buyers use earnouts instead of paying cash?: Officially, to bridge valuation gaps and align incentives — and sometimes that is true. Mechanically, an earnout converts price risk into the seller's problem: when diligence findings cut the valuation, the buyer preserves the headline by making part of it contingent, keeps their cash outlay lower, and retains control of the very operations that determine whether the contingent portion is ever paid. It also transfers execution risk — if integration underperforms, the buyer's cost of the acquisition falls automatically.
What are the risks of an earnout for the seller?: Three structural ones, before any bad faith: the targets are built on the buyer's model of your future; the post-close operations that produce the results — scheduling, fees, staffing, compensation, compliance protocols — are controlled by the buyer; and performance is measured on the buyer's books under the buyer's accounting policies. A common failure sequence: the buyer enforces compliance on day one, previously aggressive coding normalizes, revenue drops through no new decision of the seller's, and targets built on the old revenue quietly become unreachable. Every point you score costs the grader exactly one point.
How are earnout payments taxed?: Often worse than the sale itself. The IRS frequently scrutinizes contingent payments, and amounts tied to the seller's continued employment or personal performance can be reclassified from capital gains to ordinary income — a materially higher rate on money that was already uncertain. Treatment depends entirely on structure: how the earnout is documented, what it is contingent on, and how payments are characterized. This is general information, not tax advice — model the earnout's after-tax value with your CPA before signing, not after.
How do I negotiate earnout protections in a practice sale?: Five clauses carry most of the protection. One: base targets on metrics you influence — collections, not platform-level EBITDA that absorbs someone else's overhead. Two: freeze measurement definitions in the agreement — accounting policies, inclusions, exclusions. Three: operating covenants committing the buyer not to change the conditions the targets were built on — staffing, scheduling, fee schedules. Four: audit rights with a dispute mechanism short of litigation, and the intent to actually use them. Five: acceleration triggers — if the buyer sells the platform or changes your role, the earnout pays out. And the strongest protection precedes the deal: EBITDA that survives diligence intact never gets converted into an earnout at all.